Immunotherapy Combo Extends Survival in Unresectable Liver Cancer Phase III Trial
The EMERALD-3 trial shows STRIDE plus TACE improved progression-free survival to 13 months vs 9.8 months, but with significantly more side effects.
Summary
A phase III clinical trial called EMERALD-3 found that combining the immunotherapy regimen STRIDE with the standard liver cancer procedure TACE extended progression-free survival in patients with unresectable hepatocellular carcinoma. Patients receiving the combination lived without disease progression for a median of 13 months compared to 9.8 months with TACE alone. Overall survival also trended positively at 39.5 versus 34.7 months, though this did not yet reach statistical significance. However, severe side effects occurred in 71% of patients in the triple-combination group versus 29% with TACE alone. Experts are debating whether the benefit justifies the toxicity, and quality-of-life data are still needed to guide clinical decisions.
Detailed Summary
Hepatocellular carcinoma, the most common form of primary liver cancer, remains one of the deadliest cancers globally, with limited treatment options for patients whose tumors cannot be surgically removed. Transarterial chemoembolization, or TACE, has long been a standard approach for these patients but typically yields only 8 to 10 months of progression-free survival. Researchers have been working to improve these outcomes by combining TACE with newer immunotherapy agents.
The EMERALD-3 phase III trial tested whether adding the STRIDE regimen — a single dose of tremelimumab plus regular durvalumab — with or without the targeted therapy lenvatinib, could improve outcomes over TACE alone. Results presented at the 2026 ASCO annual meeting showed that patients receiving STRIDE with lenvatinib and TACE achieved a median progression-free survival of 13 months, compared to 9.8 months for TACE alone, a statistically significant improvement.
Overall survival data remain immature, but a positive trend was observed: 39.5 months in the combination group versus 34.7 months with TACE alone. Notably, the STRIDE plus TACE arm without lenvatinib also showed strong results, including a statistically significant improvement in overall survival of not yet calculable versus 32.9 months, suggesting STRIDE itself is the primary driver of efficacy.
The trade-off is significant toxicity. Grade 3 or 4 adverse events occurred in 71% of the triple-combination group and 64% of the STRIDE plus TACE group, compared to just 29% with TACE alone. Treatment discontinuation rates were also substantially higher. An expert discussant questioned whether these risks are worth the benefit without quality-of-life data.
For clinicians and patients, this trial opens a potentially meaningful new treatment pathway for liver cancer, though the optimal regimen and patient selection require further study. The findings support STRIDE plus TACE, without lenvatinib, as the more favorable starting combination pending additional data.
Key Findings
- STRIDE plus TACE improved median progression-free survival to 13 months vs 9.8 months with TACE alone
- Overall survival trended toward improvement at 39.5 vs 34.7 months, though not yet statistically significant
- STRIDE plus TACE without lenvatinib showed significant OS benefit, suggesting STRIDE drives efficacy
- Grade 3/4 adverse events occurred in 71% of triple-combination patients vs 29% with TACE alone
- Experts recommend considering STRIDE plus TACE first, reserving lenvatinib for subsequent treatment
Methodology
This is a meeting coverage news report summarizing the phase III EMERALD-3 randomized controlled trial presented at the 2026 ASCO annual meeting. MedPage Today is a credible medical news outlet targeting clinicians. Evidence is based on a phase III RCT, the highest level of clinical evidence, though OS data remain immature and full peer-reviewed publication is pending.
Study Limitations
Overall survival data are immature and the OS improvement did not reach statistical significance in the primary analysis. Full peer-reviewed publication has not yet been released, limiting detailed methodology review. Quality-of-life data, critical for assessing true patient benefit, are not yet available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.